Prostate Cancer Patients With Cardiovascular Disease Had Higher Mortality After Starting Abiraterone Acetate


Patients with advanced prostate cancer who had pre-existing cardiovascular disease had higher risk of mortality in the six months after starting abiraterone acetate (Zytiga) treatment compared with those who had no pre-existing cardiovascular disease, according to data presented during a media preview of the American Association for Cancer Research (AACR) Annual Meeting 2019, which will be held March 29–April 3, in Atlanta.

“Patients with a history of significant cardiovascular disease or uncontrolled hypertension are almost always excluded from clinical trials of abiraterone acetate,” said Grace Lu-Yao, PhD, MPH, Associate Director of Population Science at the Sidney Kimmel Cancer Center at Jefferson in Philadelphia. “However, in the real-world setting, these conditions are very common among men with prostate cancer.

To read the full press release, please visit the AACR’s website.